COMPANY PROFILE

Innoventric

Explore full profile

Innoventric develops transcatheter solutions for patients with structural heart disease

Ness Ziona, IsraelFounded 2016Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Innoventric

Developer of percutaneous devices designed to provide treatment of tricuspid regurgitation. The company's device offers functional tricuspid valve replacement that utilizes cross-caval anchoring and a unique multi-valve design, for long-lasting blood flow regulation, enabling patients with structural heart disease to improve their lifespan and quality of their life. Keywords: Pharmaceuticals and Biotechnology, Blood Flow Regulation, Heart Device, Medical Device, Percutaneous Treatment, Percutaneous Valves, Structural Heart Intervention, Treatment Services, Tricuspid Treatment.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Ness Ziona, Israel
Employees: 22
Open positions: None listed
Dealroom signal: 75.8/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, EIC, Biotech and Pharma, EIC Fund, Hard Tech, Horizon Europe, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Innoventric.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Oct 2024	$29M	$114M	JG Capital · Mivtach Shamir Holdings · EIC Fund · BRM Capital	↗
SERIES A✓Equity / VC	Nov 2021	$14M	$56M	Undisclosed	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Innoventric website traffic

Latest recorded traffic for Innoventric is 1.5K monthly website visits, up 120.6% over the last three months. Innoventric's team grew 4.8% over the past year.

Latest monthly visits1.5K 3-month web change+120.6% 1-year team growth+4.8%

Monthly website visitsAug 2022–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SESentanteDeveloping a radiation-reducing manipulator and a minimally invasive coronary robotic system for endovascular procedures	Kaunas, Lithuania	Operational	39	$9.1M	$26M
MOmoveUPAI-powered digital therapy for remote patient monitoring	City of Brussels, Belgium	Operational
BTBetalin therapeuticsBetalin's Micro Pancreas is a revolutionary regenerative micro-organ based on cell therapy. It eliminates the need for daily injections, constant blood glucose monitoring, and dietary constraints	Ramat Gan, Israel	Operational
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
HPHerantis PharmaInnovative biotech company developing disease modifying therapies for Parkinson’s disease	Helsinki, Finland	Operational
APAbility PharmaAbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer	Cerdanyola del Vallès, Spain	Operational
HTHoba TherapeuticsDeveloper of neuropathic pain and CNS therapies. The company develops biopharmaceuticals for chronic pain and hearing loss	Copenhagen, Denmark	Operational
OSOsivaxA company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections	Lyon, France	Operational